The expertise and commitment of our R&D and management teams, alongside a fruitful collaborations with academic and independent research institutes and contract research organizations, contribute to Neurim Pharmaceuticals’ remarkable successes in drug discovery and development. Neurim Pharmaceuticals has one product registered, Circadin® – prolonged release melatonin for insomnia, and several molecules in the pipeline for the treatment of other CNS disorders. Paediatric Prolonged-Release Melatonin has successfully completed a Phase III clinical trial in neurodevelopmental disabled children suffering from sleep disorders. Neurim is advancing with regulatory submissions for this product. The company’s lead drug candidate Piromelatine (Neu-P11) is a novel compound under development for sleep and cognition in Insomnia and Alzheimer’s Disease. It has completed a Phase II clinical trial for insomnia. A Phase II randomized, placebo controlled dose ranging study is underway, that is intended to evaluate efficacy and safety of Piromelatine for cognitive skills global functioning and sleep in patients with mild to moderate Alzheimer’s Disease is under way. Two more of its compounds (for neuropathic pain Alzheimer’s, and Parkinson’s Disease) are expected to reach final preclinical stages in the near term.

  • Text size: A A A
  • Circadin
  • Recent news

    • Slenyto is now available in Spain!
    • Neurim Pharmaceuticals is attending World Sleep Congress 2022, March 11-16, Rome, Italy
    • Neurim conducted a survey via Brandman Research, assessing the characteristics of insomnia in children with ASD and the distress it causes to the children and their families
  • Partners